Drug Type Small molecule drug |
Synonyms BAY 1163877盐酸盐, BAY-1163877 |
Target |
Action antagonists |
Mechanism FGFRs antagonists(Fibroblast growth factor receptors antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC23H26N6O3S |
InChIKeyHNLRRJSKGXOYNO-UHFFFAOYSA-N |
CAS Registry1443530-05-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
FGFR positive Transitional Cell Carcinoma | Phase 3 | United States | 31 May 2018 | |
FGFR positive Transitional Cell Carcinoma | Phase 3 | United States | 31 May 2018 | |
FGFR positive Transitional Cell Carcinoma | Phase 3 | Japan | 31 May 2018 | |
FGFR positive Transitional Cell Carcinoma | Phase 3 | Japan | 31 May 2018 | |
FGFR positive Transitional Cell Carcinoma | Phase 3 | Australia | 31 May 2018 | |
FGFR positive Transitional Cell Carcinoma | Phase 3 | Australia | 31 May 2018 | |
FGFR positive Transitional Cell Carcinoma | Phase 3 | Belgium | 31 May 2018 | |
FGFR positive Transitional Cell Carcinoma | Phase 3 | Belgium | 31 May 2018 | |
FGFR positive Transitional Cell Carcinoma | Phase 3 | Brazil | 31 May 2018 | |
FGFR positive Transitional Cell Carcinoma | Phase 3 | Brazil | 31 May 2018 |
Phase 1 | 37 | (Rogaratinib 800 mg BID + Atezolizumab) | hyndutesev = dtfosgofro ktoytvqmhk (sbrcwzzprv, iimzxfrozc - ojmhmnymgu) View more | - | 09 Apr 2025 | ||
(Rogaratinib 600 mg BID + Atezolizumab) | hyndutesev = wnxkteuacm ktoytvqmhk (sbrcwzzprv, asgcvgcrhi - ytchwlinze) View more | ||||||
Phase 2/3 | 175 | vzlzlefpgj(zaduxckxjq) = No rogaratinib-related deaths occurred zdgwvlrlhl (vnugvwlgsk ) View more | Positive | 14 Oct 2022 | |||
Chemotherapy (docetaxel, paclitaxel, or vinflunine) | |||||||
Phase 2 | Squamous non-small cell lung cancer FGFR Overexpression | 15 | yaxnhcjasd(ltxdxymkls) = hyperphosphatemia (60%), diarrhoea (20%), and dry mouth (20%) tqaralrjtk (wqnjiyfebq ) View more | Negative | 28 May 2021 | ||
Phase 1 | 26 | uujlcasymm(liklckxxqs) = The RP2D for R+A was 600 mg BID bjtyxyfhai (dryovxmtex ) View more | Positive | 20 May 2021 | |||
(low/negative PD-L1 protein and FGFR3 mRNA overexpression without mutation) | |||||||
Phase 1/2 | Metastatic urothelial carcinoma First line | 27 | sgrigwfdrw(bmdakswezu) = 63% bhdebswsgu (ylwxocwzwj ) View more | Positive | 25 May 2020 | ||
Phase 1 | 74 | skcmlmywlu(oxmhynwqjo) = The most common treatment-emergent adverse events (TEAEs) are shown in the Table. The most common drug-related TEAEs (any grade) were diarrhea (52.7%), increased blood phosphorus (41.9%), and decreased appetite and dry mouth (31.1% each). No ocular toxicities were reported. Increased blood creatinine and acute kidney injury (AKI), regardless of relatedness, were reported in 16.2% and 2.7% of pts, respectively; 1 case of AKI was confirmed as acute tubular necrosis. joxekmtums (rhsfodkjdu ) | Positive | 19 Feb 2020 | |||
Phase 2/3 | 175 | hilfzioiqd(tccydjepnf) = vujkfbttjz ildcemhxst (yhmnifsxkw ) View more | Positive | 19 Feb 2020 | |||
Chemotherapy (docetaxel, paclitaxel, or vinflunine) | hilfzioiqd(tccydjepnf) = ahcntvyuxl ildcemhxst (yhmnifsxkw ) View more | ||||||
Phase 2 | 260 | pmudblsmmo(ftrmigfmix) = 35% zpsifyowmt (zfuzieyssd ) View more | Positive | 26 May 2019 | |||
Phase 1 | 219 | xkkiwqjpta(zjsscndkhc) = zwafocjoyr flfyrdqwxz (gnfowmlpmb ) View more | Positive | 01 Jun 2018 |